

## Anti-PDCD1/PD-1/CD279 Antibody (Toripalimab)

### Introduction

Toripalimab is the first domestically produced anti-tumor PD-1 Antibody. Toripalimab is a targeted PD-1 Antibody. Toripalimab is a selective humanized monoclonal antibody. PD-1 Toripalimab binds to and blocks the interaction with its ligand. Toripalimab has a potent anti-tumor effect and can be used in the study of tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine tumors, nasopharyngeal carcinoma and urothelial carcinoma.

### Product parameters

Alternative Names	JS-001, Triprizumab, Treprilimab
Target Accession	Q15116
Target	PDCD1 / PD-1 / CD279
CAS number	1924598-82-2
Molecular Weight	147.3 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG4
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human PD-1, His Tag at 2 ug/mL can bind Anti-PDCD1/PD-1/CD279 Antibody (Toripalimab), EC50=0.0136 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years

## Note

1. This product is for scientific research use only.



### APEx BIO Technology

[www.apexbt.com](http://www.apexbt.com)

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

